MONOAMINE-OXIDASE INHIBITOR UPDATE - POTENTIAL ADVERSE FOOD AND DRUG-INTERACTIONS

被引:35
作者
LIPPMAN, SB
NASH, K
机构
[1] Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky
[2] Department of Psychiatry, Humana Hospital, University of Louisville, Louisville, Kentucky, 40202
关键词
D O I
10.2165/00002018-199005030-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Monoamine oxidase inhibitors (MAOIs) are medicines with potential for therapeutic gains, but they may also have adverse consequences. The risk: benefit ratio is assessed and, in appropriately selected cases, efficacy should outweigh disadvantages. Hypotension is the most prominent side-effect; yet the primary concern in the MAOI-treated person is to prevent co-exposure to substances with indirectly-acting sympathomimetic properties. Such co-utilisations from certain foods or drugs can result in dangerous hypertensive and hyperpyretic crises. A responsible individual should be involved in the administration of these drugs. The patient and family must fully understand the self-discretionary diet avoidance rules, which stress abstinence from high-tyramine foods. Drug prohibitions also emphasise elimination of indirect action sympathomimetics, but all pharmaceutical applications are always strictly controlled by the well informed physician who prescribes MAOIs. Treatment of the hypertensive crisis is urgent and includes α-blockade. Overdoses require supportive therapies and may necessitate acidification of the urine. © 1990, ADIS Press Limited. All rights reserved.
引用
收藏
页码:195 / 204
页数:10
相关论文
共 22 条
  • [1] Ayd F.J., Tyramine in wine and beer, International Drug Therapy Newsletter, 23, pp. 37-40, (1988)
  • [2] Bernstein J.G., Handbook of therapy in psychiatry, (1988)
  • [3] Brown C., Taniguchi G., Yip K., The monoamine oxidase inhibitor-tyramine interaction, Journal of Clinical Pharmacology, 29, pp. 529-532, (1989)
  • [4] Christopher B., Kerwin R., Rediscovering monoamine oxidase inhibitors, British Medical Journal, 298, pp. 345-346, (1989)
  • [5] Dilsaver S.C., Panic disorder, American Family Physician, 39, pp. 167-172, (1989)
  • [6] Ferguson J.M., Interaction of aspartame and carbohydrates in an eating-disordered patient, American Journal of Psychiatry, 142, (1985)
  • [7] Goodman L.S., Gilman A., The pharmacological basis of therapeutics, (1980)
  • [8] Hannah P., Glover V., Sander M., Tyramine in wine and beer, Lancet, 1, (1988)
  • [9] Jenike M.A., The use of monoamine oxidase inhibitors in the treatment of elderly, depressed patients, Journal of the American Geriatrics Society, 32, pp. 571-575, (1984)
  • [10] Lippmann S., Baldwin H., Manshadi M., Combined trimipramine/phenelzine treatment of depression: case report, Journal of Clinical Psychiatry, 43, pp. 430-431, (1982)